Suppr超能文献

人多谱系 3D 球体作为肝脂肪变性和纤维化的模型。

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.

机构信息

Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.

Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, SE-431 83 Gothenburg, Sweden.

出版信息

Int J Mol Sci. 2019 Apr 2;20(7):1629. doi: 10.3390/ijms20071629.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.

摘要

非酒精性脂肪性肝病 (NAFLD) 是西方国家最常见的肝脏疾病。尽管 NAFLD 的患病率很高,但疾病进展的潜在生物学机制尚不清楚,也没有批准的药物可用于治疗非酒精性脂肪性肝炎 (NASH),这是该病的最严重形式。因此,迫切需要开发先进的体外人类细胞系统来研究疾病机制和药物反应。我们试图创建一种遗传上易患 NAFLD 的类器官系统,并通过添加游离脂肪酸来诱导其脂肪变性和纤维化。我们使用由肝细胞 (HepG2) 和肝星状细胞 (LX-2) 组成的多谱系 3D 球体,其生理比例为 24:1。HepG2 和 LX-2 细胞均为 I148M 序列变异的纯合子,这是 NAFLD 的最强遗传决定因素。我们证明肝星状细胞有助于 3D 球体的紧凑性。然后,我们表明,暴露于游离脂肪酸会导致球体中脂肪和胶原的积累。最后,通过用利拉鲁肽或 Elafibranor 孵育球体,可挽救这种积累,这两种药物均处于治疗 NASH 的临床试验中。总之,我们已经建立了一种简单、易于处理的多谱系 3D 球体体外遗传诱导 NAFLD 模型。该工具可用于了解脂质积累诱导纤维化早期阶段涉及的分子机制。此外,它可以用于使用高通量药物筛选来鉴定治疗 NASH 的新化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cb1/6480107/fd407f8e2bd4/ijms-20-01629-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验